Close Correlation of 1-β-D-Arabinofuranosylcytosine 5'-Triphosphate, an Intracellular Active Metabolite, to the Therapeutic Efficacy of N4-Behenoyl-1-β-D-arabinofuranosylcytosine Therapy for Acute Myelogenous Leukemia

Takahiro Yamauchi,1, 3 Yasukazu Kawai,1 Nobuyuki Goto,2 Shinji Kishi,1 Shin Imamura,1 Akira Yoshida,1 Yoshimasa Urasaki,1 Toshihiro Fukushima,1 Hiromichi Iwasaki,1 Hiroshi Tsutani,1 Mikio Masada1 and Takanori Ueda1

1First Department of Internal Medicine and 2Department of Hospital Pharmacy, Fukui Medical University, 23 Shimoaizuki, Matsuoka, Fukui 910-1193

N4-Behenoyl-1-β-D-arabinofuranosylcytosine (BHAC), a prodrug of 1-β-D-arabinofuranosylcytosine, is used effectively for the treatment of leukemia in Japan. BHAC therapy may be more effective if it is delivered in conjunction with monitoring of 1-β-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP), the intracellular active metabolite of ara-C derived from BHAC. However, previous monitoring methods for ara-CTP were insufficiently sensitive. Here, using our new sensitive method, we evaluated the ara-CTP pharmacokinetics in relation to the therapeutic response in 11 acute myelogenous leukemia patients who received a 2-h infusion of BHAC (70 mg/m²) in combination remission induction therapy. ara-CTP could be monitored at levels under 1 µM. BHAC maintained effective levels of plasma ara-C and intracellular ara-CTP for a longer time, even compared with historical values of high-dose ara-C. The area under the concentration-time curve of ara-CTP was significantly greater in the patients with complete remission than in the patients without response. This greater amount of ara-CTP was attributed to the higher ara-CTP concentrations achieved in the responding patients. There was no apparent difference of plasma ara-C pharmacokinetics between the two groups. Thus, for the first time, the ara-CTP pharmacokinetics was evaluated in relation to the therapeutic effect of BHAC, and the importance of ara-CTP was proven. Administration of optimal BHAC therapy may require monitoring of the ara-CTP pharmacokinetics in each individual patient.

Key words: BHAC — ara-C — ara-CTP — Clinical pharmacokinetics — AUC

1-β-D-Arabinofuranosylcytosine (ara-C) is one of the most effective anticancer agents in the treatment of leukemia.1–3 The administration of ara-C at a conventional dose in combination with other antileukemic drugs has markedly improved remission induction rates for acute myelogenous leukemia (AML).1–3 As regards the mechanism of action, after being transported into leukemic cells, ara-C is phosphorylated to 1-β-D-arabinofuranosylcytosine 5'-monophosphate and then to its active metabolite, 1-β-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP).4 ara-CTP inhibits DNA polymerases in competition with deoxycytidine 5'-triphosphate.5–7 A small portion of ara-CTP is incorporated into the DNA strand and terminates the DNA elongation.8 Consequently, ara-C exerts its cytotoxic effect by inhibiting DNA synthesis. Therefore, intracellular ara-CTP is a key metabolite for the mechanism of action,2–8 and the cytotoxicity of ara-C is S phase-specific and time-dependent.9

While the cytotoxic effect of ara-C is time-dependent, the drug is rapidly inactivated to 1-β-D-arabinofuranosyluracil by cytidine deaminase in the plasma.4, 10 To overcome this dilemma, several derivatives of ara-C, which are long-acting or deaminase-resistant, have been evaluated.11–14 N4-Behenoyl-1-β-D-arabinofuranosylcytosine (BHAC) is one of the acyl derivatives of ara-C, which has a long-chain fatty acyl group at the 4-amino position of ara-C,11, 12 and thereby is resistant to inactivation by cytidine deaminase.12 BHAC was proved to exhibit cytotoxicity to various experimental tumors regardless of the treatment schedule, mainly because of its resistance to deamination.11, 12 Clinically, BHAC has been used effectively in combination remission induction therapy for AML patients for over 15 years in Japan, and has provided over 70% remission rates.15–17

The mechanism of action of BHAC is thought to be substantially the same as that of ara-C.18 In the plasma, BHAC is converted into ara-C by ω- and β-oxidation of the acyl moiety, and the resultant ara-C is transported into leukemic cells.11, 12, 18 In the cells, the ara-C is phosphorylated to ara-CTP. Again, ara-CTP is thought to be a key metabolite for the cytotoxic effect.18

The importance of ara-CTP has been already shown clinically in high-dose ara-C therapies by Plunkett et al.19, 20 They demonstrated that intracellular ara-CTP was not predicted by the plasma ara-C pharmacokinetics, and
that the therapeutic efficacy was closely correlated to the amount of intracellular ara-CTP. On the other hand, the significance of ara-CTP was seldom described in conventional-dose ara-C or BHAC therapy because the previous detection methods for ara-CTP were insufficiently sensitive.23

There are several reports on the pharmacokinetic study of BHAC, including ours.22–24 We have already reported the pharmacokinetics of plasma BHAC and plasma ara-C as a metabolite of BHAC, during a 90-min intravenous infusion of conventional-dose BHAC.25 In that study, BHAC was well maintained in the plasma and, at the same time, it was converted slowly into ara-C. Consequently, the plasma ara-C concentration was maintained continuously by BHAC administration. We proved that this deaminase-resistant prodrug worked as a long-acting ara-C.24

If the intracellular ara-CTP is monitored during BHAC therapy, the pharmacokinetic study may be more informative because the active metabolite of BHAC is ara-CTP. Furthermore, if the importance of ara-CTP from the viewpoint of the therapeutic efficacy of BHAC is clinically demonstrated, the optimal BHAC therapy may be constructed based on an understanding of the ara-CTP pharmacokinetics.

Recently, we successfully monitored ara-CTP in leukemic cells of AML patients receiving low- or conventional-dose ara-C or BHAC by means of our new sensitive determination method.25,26 In that preliminary report, we noted that we would evaluate the relationship between the ara-CTP pharmacokinetics and the therapeutic outcome.26 Thus, in the present study, we included new patients and evaluated the ara-CTP pharmacokinetics in relation to the therapeutic response in AML patients receiving conventional-dose BHAC in combination remission induction therapy.

MATERIALS AND METHODS

Chemicals and enzymes ara-C, ara-CTP and bacterial alkaline phosphatase (EC 3.1.3.1) were purchased from Sigma Chemical Co. (St. Louis, MO). Na2HPO4, acetoni-trile, NaCl, Tris, perchloric acid, KOH, and dextran were purchased from Asahi Chemical Industry Co., Ltd. (Tokyo).27 Anti-ara-C serum was kindly supplied by Amersham International (Buckinghamshire, UK). Charcoal was purchased from J. T. Baker Chemical Co. (Phillipsburg, NJ). [5-3H]-ara-C (30 Ci/mmol) was purchased from Amersham International (Buckinghamshire, UK). Anti-ara-C serum was kindly supplied by Asahi Chemical Industry Co., Ltd. (Tokyo).27

Patients and treatments Eleven patients eligible for the pharmacological studies were diagnosed as having AML (M1, 2 patients; M2, 7 patients; M4, 2 patients by French-American-British classification) by the standard hematological and clinical criteria, confirmed by the examination of bone marrow. They were 5 males and 6 females. Median age was 65 (range: 35–83). Informed consent for this investigation was obtained in advance. BHAC at 70 mg/m2 was administered by intravenous infusion for 2 h twice daily in combination with 6-mercapto purine (70 mg/m2), etoposide (70 mg/m2) and idarubicin (12 mg/m2) as remission induction therapy.29 Complete remission (CR) was considered established when blasts became less than 5% with normal levels of granuloid and erythroid series in bone marrow, and with normal levels of peripheral leukocytes and platelets.

Sample collection Blood samples were obtained before the therapy and at 0, 1, 2, 4, 6 and 10 h after the end of BHAC administration. The blood samples were then put into heparinized tubes containing tetrahydrofuran, an inhibitor of cytidine deaminase, at a final concentration of 0.1 mM.28 The plasma and the mononuclear cells including leukemic blasts were fractionated by a Ficoll-Paque density centrifugation procedure.30 Both the plasma ara-C concentration and the ara-CTP concentration in leukemic cells were measured. In this study, we did not measure the plasma BHAC concentration because it was a primary focus in our previous study.24

Determination of the plasma ara-C concentration The plasma ara-C concentration was measured using the radioimmunoassay described by Shimada et al. with minor modifications.27 In brief, 50 µl of the plasma was mixed with 200 µl of 0.01 M phosphate buffer (containing 0.5% bovine serum albumin and 0.9% NaCl, pH 7.4), 50 µl of anti-ara-C serum, and 50 µl of [5-3H]-ara-C. The mixture was incubated for 16 h at 4°C. Five hundred microliters of dextran-coated charcoal, which was composed of 100 mg of dextran and 1000 mg of charcoal per 100 ml of the above phosphate buffer, was added to the mixture. The whole was allowed to stand for 30 min at 4°C, and centrifuged (10000 g, 15 min, 4°C). The radioactivity of the supernatant was determined. The detection limit was 0.4 nM.

Determination of the intracellular ara-CTP concentration The intracellular ara-CTP concentration was determined by the newly established method we previously reported.25 The nucleotide pool including ara-CTP was extracted from leukemic cells (2×107 cells) using cold perchloric acid (final concentration 0.3 M), and then neutralized by KOH. ara-CTP was separated from the other nucleotides by high-performance liquid chromatography with an ion-exchange column, TSK gel DEAE-2 SW (250×4.6 mm inside diameter, particle size 5 µm, TOSOH Corp., Tokyo). The elution was performed with 0.05 M Na2HPO4 (pH 6.9)-20% acetoni-trile at a constant flow rate of 0.7 ml/min at ambient temperature. ara-CTP was monitored at 269 nm. The ara-CTP fraction was freeze-dried, dissolved again in 300 µl of 0.1 M Tris buffer (pH 10.1), and mixed with alkaline phosphatase (10 units). The mixture was incubated for 12 h at 55°C, with the result
that ara-CTP was dephosphorylated to ara-C. The ara-C derived from ara-CTP was measured using the radioimmunoassay described above. The obtained value of ara-CTP was divided by the packed cell volume occupied by the cell number \((2 \times 10^7 \text{ cells})\) used to determine the intracellular concentration. The detection limit was 20 nM.

**Pharmacokinetic analysis** The area under the concentration-time curve from 0 to 24 h (AUC) and the pharmacokinetic parameters were obtained by moment analysis.30)

**RESULTS**

Our new sensitive method enabled the measurement of ara-CTP concentrations under 1 \(\mu\text{M}\). The mean±SD concentration-time curves of the plasma ara-C and the intracellular ara-CTP of all the patients are shown in Fig. 1. The pharmacokinetic parameters (mean±SD values) are summarized in Table I.

**Pharmacokinetics of plasma ara-C and intracellular ara-CTP** The plasma ara-C reached the maximal concentration (\(C_{\text{max}}\)) at the end of the infusion and decreased gradually thereafter. The intracellular ara-CTP reached the \(C_{\text{max}}\) at 4 h from the end of the infusion and declined gradually thereafter. The coefficient of variation of the \(C_{\text{max}}\), the elimination half-life (\(t_{1/2}\)) and the AUC for ara-CTP were 74, 52, and 46%, respectively. Thus, the intracellular pharmacokinetics varied widely among patients. The \(C_{\text{max}}\) and the AUC of the intracellular ara-CTP were not predicted by the respective parameters of the plasma ara-C (Fig. 2) \((P=0.79 \text{ for the } C_{\text{max}}, P=0.66 \text{ for the AUC, Spearman’s correlation test})\).

![Fig. 1. Mean±SD concentration-time curves of the plasma ara-C (A) and the intracellular ara-CTP (B) in 11 acute myelogenous leukemia patients who received the 2-h intravenous infusion of 70 mg/m² BHAC.](image_url)

|                      | ara-C         | ara-CTP       |
|----------------------|--------------|---------------|
|                      | \(C_{\text{max}}\) (\(\mu\text{M}\)) | AUC (\(\mu\text{M} \cdot \text{h}\)) | \(t_{1/2}\) (h) | \(C_{\text{max}}\) (\(\mu\text{M}\)) | AUC (\(\mu\text{M} \cdot \text{h}\)) | \(t_{1/2}\) (h) |
| All patients         | Mean         | 0.12          | 0.84          | 7.3          | 3.72          | 30.99         | 10.3          |
|                      | SD           | 0.06          | 0.45          | 6.4          | 2.77          | 14.18         | 5.3           |
| CR group             | Mean         | 0.14          | 0.81          | 6.7          | 4.73          | 39.20         | 9.9           |
|                      | SD           | 0.06          | 0.43          | 3.5          | 2.97          | 10.06         | 5.1           |
| NR group             | Mean         | 0.10          | 0.94          | 7.7          | 1.93          | 16.63         | 10.6          |
|                      | SD           | 0.04          | 0.59          | 7.3          | 1.13          | 6.03          | 6.8           |

Abbreviations: ara-C, 1-\(\beta\)-D-arabinofuranosylcytosine; ara-CTP, 1-\(\beta\)-D-arabinofuranosylcytosine 5’-triphosphate; \(C_{\text{max}}\), maximal concentration; AUC, area under the concentration-time curve; \(t_{1/2}\), elimination half-life; CR, complete response; NR, no response.
Comparison of the pharmacokinetics between CR and no response (NR) groups

Seven patients reached CR (CR group) while 4 did not respond to the treatment (NR group). The total dose of BHAC administered to each patient during the induction therapy was 1182 ± 250 mg/m² (mean ± SD) in the CR group, and 1026 ± 80 mg/m² in the NR group. Thus, there was no significant difference between the total doses in the two groups ($P = 0.42$, Mann-Whitney test). The pharmacokinetic parameters were compared (Table I). The concentration-time curves of the plasma ara-C in the two groups appeared to be similar to each other (Fig. 3A). The values for the $C_{\text{max}}$, the AUC, and the $t_{1/2}$ of the plasma ara-C were not different between the 2 groups. In contrast, the curve of the intracellular ara-CTP for the CR group was higher than that for the NR group (Fig. 3B). The intracellular ara-CTP concentrations at all time points including the $C_{\text{max}}$ were higher in the CR group than in the NR group, although the difference was not statistically significant ($P = 0.13$ for $C_{\text{max}}$, Mann-Whitney test). In addition, the ara-CTP was eliminated with similar $t_{1/2}$ values in both groups. Consequently, the AUC of the intracellular ara-CTP was significantly greater in the CR group than in the NR group ($P = 0.02$, Mann-Whitney test) (Fig. 4, Table I).

Fig. 2. Relationship of $C_{\text{max}}$ (A) and AUC (B) between plasma ara-C and intracellular ara-CTP.

Fig. 3. Mean concentration-time curves of the plasma ara-C (A) and the intracellular ara-CTP (B) in the CR group (7 patients) and NR group (4 patients) receiving the 2-h intravenous infusion of 70 mg/m² BHAC. Closed circles, CR group; open circles, NR group.
DISCUSSION

In the present study, we successfully monitored the intracellular ara-CTP concentrations during BHAC administration in combination therapy. Moreover, we evaluated its pharmacokinetics in relation to the therapeutic efficacy. The ara-CTP pharmacokinetics varied widely among patients, and was not correlated to the plasma ara-C concentrations. The AUC of ara-CTP was significantly greater in the CR group than in the NR group, which was attributed to the higher ara-CTP concentrations achieved in patients with CR.

As shown in Fig. 1, BHAC maintained both the plasma ara-C and the intracellular ara-CTP for a long time. The $t_{1/2}$ values of the plasma ara-C and the intracellular ara-CTP were longer, even compared with the historical values (2.8 h and 3.4 h, respectively) during a 2-h infusion of high-dose ara-C (3 g/m²). BHAC prolonged the ara-C retention in the plasma because the drug is resistant to deamination and is converted slowly into ara-C. Moreover, we demonstrated in our prior in vitro study that the maintenance of ara-C in the medium was crucial to sustaining the intracellular ara-CTP in HL60 leukemic cells. As long as ara-C was present in the extracellular fluid, it was transported into the cells and phosphorylated to maintain ara-CTP, whereas the intracellular ara-CTP was rapidly eliminated if the extracellular ara-C was washed out. Therefore, during BHAC therapy, the maintenance of ara-CTP in leukemic cells would be due to the prolonged retention of ara-C in the plasma. Thus, BHAC maintained both the plasma ara-C and the intracellular ara-CTP for a long time.

Yoshida et al. evaluated the ara-CTP pharmacokinetics during a 1-h infusion of high-dose BHAC (700 mg/m²). In their study, the $C_{max}$, the $t_{1/2}$, and the AUC of ara-CTP were 0.081 µg/10⁷ cells (roughly equal to 20 µM), 13.6 h, and 1.224 µg ⋅ h/10⁷ cells (roughly equal to 250 µM ⋅ h), respectively. These values were compared with our pharmacokinetic results for 70 mg/m² BHAC since in both studies BHAC was similarly administered as a short-hour infusion. To standardize the values, the $C_{max}$ and the AUC that were produced per 1 mg of BHAC were calculated. The ratio values between the $C_{max}$ and the dose were 0.029 (calculated as the ratio of 20/700) for Yoshida et al. and 0.048 (3.42/70) for us, and these are similar. This ratio represents the relative height of the intracellular ara-CTP concentration achieved by administering 1 mg BHAC. The ratio values between the AUC and the dose were 0.36 (250/700) for Yoshida et al. and 0.43 (30.76/70) for us, and these are also very similar to each other. This ratio represents the amount of the intracellular ara-CTP produced by 1 mg BHAC, which is interpreted as the efficiency of ara-CTP production. The $t_{1/2}$ values for both doses were also close to each other. Thus, these two doses produced ara-CTP with the same efficiency despite the 10-fold difference. This suggests that ara-CTP would be generated in a dose-dependent manner and this ara-CTP production would not be saturated at doses up to at least 700 mg/m².

Conventional-dose BHAC is usually used at doses from 150 to 200 mg/m². In our protocol, 140 mg/m² BHAC was used per day. This dose was divided into halves and the half dose (70 mg/m²) was infused twice daily. Thus, the daily dosage (140 mg/m²/day) is regarded as conventional. Strictly speaking, we analyzed the pharmacokinetics of BHAC at 70 mg/m², substantially half the conventional dose. However, the pharmacokinetic data obtained in our study would be applicable to the conventional dose because the same efficiency of ara-CTP pro-

---

**Fig. 4.** Comparison of the AUC of plasma ara-C (A) or intracellular ara-CTP (B) between the CR group (7 patients) and NR group (4 patients).
duction was suggested at doses ranging from 70 to 700 mg/m².

ara-CTP has already been reported as a crucial determinant in high-dose ara-C therapies (3 g/m²).19, 20) Plunkett et al. demonstrated that greater AUC of ara-CTP was closely correlated to a successful therapeutic outcome during a 2-h infusion of 3 g/m² ara-C.19) They showed that the $t_{1/2}$ of ara-CTP was significantly longer in patients with CR, whereas no significant difference was found in $C_{max}$ between the CR and NR groups. This suggested that the greater AUC of ara-CTP in the CR group was mainly attributed to the longer ara-CTP retention in leukemic cells. However, in our present BHAC study, the AUC of the intracellular ara-CTP was significantly greater in the CR group, but the $t_{1/2}$ values were not very different between the two groups. The greater AUC of ara-CTP during BHAC therapy was mainly due to the higher ara-CTP concentrations achieved in leukemic cells. It would be difficult to compare directly these two therapies because the doses, the doses, and the backgrounds of the patients were all different. However, in the intracellular metabolism of ara-C, deoxycytidine kinase is thought to be a key enzyme for the production of ara-CTP, while cytidine deaminase is regarded as responsible for the degradation.7, 9, 34) If so, the mechanisms of drug resistance may be different between 2-h infusions of BHAC and ara-C.

In contrast to the intracellular behavior of ara-CTP, no difference was found in the plasma ara-C pharmacokinetics between the CR and NR groups. In addition, the total doses of BHAC administered through this combination induction therapy were not different between the two groups. In other words, leukemic cells in both groups were equally loaded with the same AUC of plasma ara-C in the same manner. Thus, it is suggested that the difference of the ara-CTP production would depend mainly on the nature of the leukemic cells.

The Japan Adult Leukemia Study Group (JALSG) compared the therapeutic effects of BHAC and ara-C in combination induction therapy for AML patients in a large cohort study.15) In that study, conventional-dose ara-C (80 mg/m²) was given as a continuous intravenous infusion while 200 mg/m² BHAC, equivalent to 80 mg/m² ara-C, was used as a 3-h intravenous infusion once daily. The study concluded that BHAC resulted in poorer CR and lower event-free survival rates than ara-C. However, many pharmacokinetic studies had previously revealed that continuous ara-C infusion produced ara-CTP most effectively, and therefore it is the best administration schedule for ara-C.19, 20) Conversely, BHAC has been used empirically as a 3-h infusion once daily, only because its cytotoxic effect was reported to be independent of the treatment schedule in animal tumor models.11, 12, 15–17) The retrospective analysis of this comparative study also suggested that BHAC was not equivalent to ara-C in terms of the cytotoxic intensity, despite the premise that the doses of both agents were adjusted to be equivalent on the basis of their respective molecular weights.36) At least, our present findings suggest that BHAC should be given twice daily because the $t_{1/2}$ of ara-CTP is almost half a day. Thus, if a better schedule for BHAC is used based on the clinical pharmacokinetics of ara-CTP, it may provide a different result in the comparison between BHAC and ara-C.

ara-CTP has been reported to be a crucial parameter for the prediction of the therapeutic efficacy of high-dose ara-C therapy.19, 20) On the other hand, the importance of ara-CTP has not yet been clinically confirmed with regard to BHAC therapy. This is the first report to relate the clinical pharmacology of ara-CTP to the therapeutic response to BHAC treatment. It would be more accurate to evaluate the clinical response to single therapy with BHAC alone. However, this is difficult because BHAC is usually combined with other antileukemic agents in the treatment of AML. Nevertheless, the present pharmacokinetic results strongly suggest that intracellular ara-CTP concentration can be a predictor of the response to BHAC-based combination therapy. ara-C is thought to inhibit DNA synthesis partly through the inhibition of DNA polymerases by ara-CTP and partly through the incorporation of the drug into DNA strands. Even for the latter, the formation of ara-CTP is essential. ara-CTP inhibits DNA polymerases dose-dependently, competing with deoxycytidine 5'-triphosphate.5) It would be possible to predict the degree of inhibition of DNA polymerases by a given ara-CTP concentration from a knowledge of the kinetic parameters of DNA polymerases, including the Michaelis constant and the inhibition constant, and the intracellular ara-CTP and deoxycytidine triphosphate concentrations.6, 37) The inhibition constant values for polymerases $\alpha$ and $\beta$ for ara-CTP are reported to be 1.5 $\mu$M and 8 $\mu$M, respectively in primary AML cells.38) These in vitro values cannot be directly translated to the clinical situation.6) However, it is suggested that individual leukemic cells might have a target ara-CTP concentration for the maximal inhibition of DNA synthesis. Thus, for the maximal therapeutic effect, the optimal administration schedule for BHAC may be directed on the basis of the intracellular ara-CTP pharmacokinetics in each patient.

ACKNOWLEDGMENTS

This work was supported in part by a Grant-in-Aid from the Ministry of Health and Welfare, Japan. We thank Ms. Shinobu Niwa for her technical assistance.

(Received May 18, 2001/Revised July 6, 2001/Accepted July 16, 2001)
REFERENCES

1) Berman, E. Chemotherapy in acute myelogenous leukemia: high dose, higher expectations? *J. Clin. Oncol.*, 13, 1–4 (1995).

2) Rowe, J. M. What is the best induction regimen for acute myelogenous leukemia? *Leukemia*, 12 (Suppl. 1), S16–S19 (1998).

3) Fukushima, T. and Ueda, T. Current situation and perspective for treatment of acute myelogenous leukemia in adults. *Jpn. J. Cancer Chemother.*, 25, 295–302 (1998) (in Japanese).

4) Chou, T.-C., Hutchinson, D. J., Schmid, F. A. and Philips, F. S. Metabolism and selective effects of 1-β-D-arabinofuranosylcytosine in L1210 and host tissues in vivo. *Cancer Res.*, 35, 225–236 (1975).

5) Graham, F. L. and Whitmore, G. F. The effect of 1-β-D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. *Cancer Res.*, 30, 2627–2635 (1970).

6) Graham, F. L. and Whitmore, G. F. Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine 5′-triphosphate. *Cancer Res.*, 30, 2636–2644 (1970).

7) Chou, T.-C., Artin, Z., Clarkson, B. D. and Philips, F. S. Metabolism of 1-β-D-arabinofuranosylcytosine in human leukemic cells. *Cancer Res.*, 37, 3561–3570 (1977).

8) Spriggs, D., Robbins, G., Ohno, Y. and Kufe, D. Detection of 1-β-D-arabinofuranosylcytosine incorporation into DNA in vivo. *Cancer Res.*, 47, 6532–6536 (1987).

9) Ozawa, S., Sugiyama, Y., Mitsuhushi, J. and Inaba, M. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. *Cancer Res.*, 49, 3823–3828 (1989).

10) Kamiya, K., Uchida, M., Ueda, T. and Nakamura, T. Studies on intracellular kinetics of ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable administration of ara-C. *Jpn. Soc. Cancer Ther.*, 25, 1419–1427 (1990) (in Japanese).

11) Aoshima, M., Tsukagoshi, S., Sakurai, Y., Oh-ishi, J., Ishida, T. and Kobayashi, H. Antitumor activities of newly synthesized N4-acyl-1-β-D-arabinofuranosylcytosine. *Cancer Res.*, 26, 2726–2732 (1976).

12) Aoshima, M., Tsukagoshi, S., Sakurai, Y., Oh-ishi, J., Ishida, T. and Kobayashi, H. N4-Behenoyl-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent. *Cancer Res.*, 37, 2481–2486 (1977).

13) Ueda, T., Nakamura, T., Kagawa, D., Uchida, M., Domae, N., Sugiyama, M., Ueda, Y., Sasada, M. and Uchino, H. Clinical pharmacology of N4-palmityl-1-β-D-arabinofuranosylcytosine in patients with hematologic malignancies. *Cancer Chemother. Pharmacol.*, 24, 371–375 (1989).

14) Ueda, T., Kamiya, K., Urasaki, Y., Wataya, S., Kawai, Y., Tsutani, H., Sugiyama, M. and Nakamura, T. Clinical pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate, an orally administered long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine. *Cancer Res.*, 54, 109–113 (1994).

15) Kimura, K., Ohno, R., Amaki, I., Hattori, K., Hirota, Y., Hoshino, A., Ichimaru, M., Ito, M., Kimura, I., Maekawa, T., Masaoka, T., Nakamura, T., Ogawa, M., Oguro, M., Ohta, K., Osamura, S., Shimoyama, M., Takaku, F., Uzuka, Y. and Yamada, K. Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-β-D-arabinofuranosylcytosine. *Cancer Res.*, 56, 1913–1917 (1995).

16) Ohno, R., Kato, Y., Nagura, E., Murase, T., Okumura, M., Yamada, H., Ogura, M., Minami, S., Suzuki, H., Morishima, Y., Yokomaku, S., Ezaki, K., Kodera, Y., Kawashima, K., Saito, H. and Yamada, K. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length. *J. Clin. Oncol.*, 4, 1740–1747 (1986).

17) Yoshida, M., Suda, K., Tsuboyama, A., Sasaki, R., Kitagawa, S., Kano, Y., Muto, Y., Takaku, F., Sakamoto, S. and Miura, Y. Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukemia in adults. *Eur. J. Haematol.*, 43, 1–6 (1989).

18) Higashigawa, M., Ochiai, H., Ohkubo, T., Kawasaki, H., Nobori, T., Kamiya, H. and Sakurai, M. Incorporation of N4-behenoyl-1-β-D-arabinofuranosylcytosine into DNA as a 1-β-D-arabinofuranosylcytosine. *Med. Oncol. Tumor Pharmacother.*, 5, 265–271 (1988).

19) Plunkett, W., Iacoboni, S., Estey, E., Danhauser, L., Lillemark, J. O. and Keating, M. J. Pharmacologically directed ara-C therapy for refractory leukemia. *Semin. Oncol.*, 12 (Suppl. 3), 20–30 (1985).

20) Heinemann, V., Estey, E., Keating, M. J. and Plunkett, W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. *J. Clin. Oncol.*, 7, 622–628 (1989).

21) Plunkett, W., Hug, V., Keating, M. J. and Chubb, S. Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. *Cancer Res.*, 40, 588–591 (1980).

22) Yamada, K., Kawashima, K., Kato, Y., Morishima, Y., Tanimoto, M. and Ohno, R. Pharmacology and clinical studies of N4-behenoyl-1-β-D-arabinofuranosylcytosine. *Recent Results Cancer Res.*, 70, 219–229 (1980).

23) Kimura, K., Ohno, R., Amaki, I., Hattori, K., Hirota, Y., Hoshino, A., Ichimaru, M., Ito, M., Kimura, I., Maekawa, T., Masaoka, T., Nakamura, T., Ogawa, M., Oguro, M., Ohta, K., Osamura, S., Shimoyama, M., Takaku, F., Uzuka, Y. and Yamada, K. Phase I clinical and pharmacokinetic study of N4-behenoyl-1-β-D-arabinofuranosylcytosine. *Med.
Oncol. Tumor Pharmacother., 3, 15–24 (1986).
24) Ueda, T., Nakamura, T., Ando, S., Kagawa, D., Sasada, M., Uchino, H., Johno, I. and Akiyama, Y. Pharmacokinetics of N\(^4\)-behenoyl-1-\(\beta\)-D-arabinofuranosylcytosine in patients with acute leukemia. Cancer Res., 43, 3412–3416 (1983).
25) Yamauchi, T., Ueda, T. and Nakamura, T. A new sensitive method for determination of intracellular 1-\(\beta\)-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo. Cancer Res., 56, 1800–1804 (1996).
26) Yamauchi, T., Kawai, Y., Kishi, S., Goto, N., Urasaki, Y., Imamura, S., Fukushima, T., Yoshida, A., Iwashiki, H., Tsutani, H., Masada, M. and Ueda, T. Monitoring of intracellular 1-\(\beta\)-D-arabinofuranosylcytosine 5'-triphosphate in 1-\(\beta\)-D-arabinofuranosylcytosine therapy at low and conventional doses. Jpn. J. Cancer Res., 92, 546–553 (2001).
27) Shimada, N., Ueda, T., Yokoshima, T., Oh-ishi, J. and Ohoka, T. A sensitive and specific radioimmunoassay for 1-\(\beta\)-D-arabinofuranosylcytosine. Cancer Lett., 24, 173–178 (1984).
28) Ho, D. H. W. and Frei, E., III. Clinical pharmacology of 1-\(\beta\)-D-arabinofuranosylcytosine. Clin. Pharmacol. Ther., 12, 944–954 (1971).
29) Fallon, H. J., Frei, E., III, Davidson, J. D., Trier, J. S. and Burk, D. Leukocyte preparations from human blood: evaluation of their morphologic and metabolic state. J. Lab. Clin. Med., 59, 779–791 (1962).
30) Yamaoka, K., Nakagawa, T. and Uno, T. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm., 6, 547–558 (1978).
31) Liliemark, J. O., Plunkett, W. and Dixon, D. O. Relationship of 1-\(\beta\)-D-arabinofuranosylcytosine to plasma 1-\(\beta\)-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-\(\beta\)-D-arabinofuranosylcytosine. Cancer Res., 45, 5952–5957 (1985).
32) Yoshida, T., Kobayashi, K., Okabe, Y., Okumura, H., Matano, S., Kanno, M., Takeda, Y., Ohtake, S., Nakamura, S. and Matsuda, T. Plasma and leukemia cell pharmacokinetics of high-dose N\(^3\)-behenoyl-1-\(\beta\)-D-arabinofuranosylcytosine in acute leukemia patients. J. Clin. Pharmacol., 34, 52–59 (1994).
33) Plunkett, W., Liliemark, J. O., Adams, T. M., Nowak, B., Estey, E., Kantarjian, H. and Keating, M. J. Saturation of 1-\(\beta\)-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-\(\beta\)-D-arabinofuranosylcytosine therapy. Cancer Res., 47, 3005–3011 (1987).
34) Momparler, R. L. A model for the chemotherapy of acute leukemia with 1-\(\beta\)-D-arabinofuranosylcytosine. Cancer Res., 34, 1775–1787 (1974).
35) Kobayashi, T., Miyawaki, S., Tanimoto, M., Kuriyama, K., Murakami, H., Yoshida, M., Minami, S., Minato, K., Tsubaki, K., Ohmoto, E., Oh, H., Jinai, I., Sakamaki, H., Hiraoka, A., Kanamaru, A., Takahashi, I., Saito, K., Naoe, T., Yamada, O., Asou, N., Kagemya, S., Emi, N., Matsuoka, A., Tomonaga, M., Saito, H., Ueda, R. and Ohno, R. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, with or without ubenimex after maintenance/ intensification therapy in adult acute myeloid leukemia. J. Clin. Oncol., 14, 204–213 (1996).
36) Miyawaki, S., Kobayashi, T., Tanimoto, M., Kuriyama, K., Murakami, H., Yoshida, M., Minami, S., Minato, K., Tsubaki, K., Omoto, E., Oh, H., Jinai, I., Sakamaki, H., Hiraoka, A., Kanamaru, A., Takahashi, I., Saito, K., Naoe, T., Yamada, O., Asou, N., Kageyama, S., Emi, N., Ueda, T., Tomonaga, M., Saito, H., Ueda, R. and Ohno, R. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. Int. J. Hematol., 70, 56–57 (1999).
37) Wang, L.-M., White, J. C. and Capizzi, R. L. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology. Cancer Chemother. Pharmacol., 25, 418–424 (1990).
38) Townsend, A. J. and Cheng, Y.-C. Sequence-specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro: visualization of chain elongation on a defined template. Mol. Pharmacol., 32, 330–339 (1987).